Chemical subgroup
L01EC – BRAF-Serin-Threoninkinase-Inhibitoren
9Decisions
16Patient groups
Added benefit by patient group
- Considerable5
- Non-quantifiable2
- Not proven9
Decisions, newest first
- 2025-03-20BraftoviEncorafenibNot proven: 3 of 3 patient groups
- 2024-10-17FinleeDabrafenibConsiderable: 1 of 3 patient groupsNon-quantifiable: 2 of 3 patient groups
- 2020-12-17BraftoviEncorafenibConsiderable
- 2019-03-22BraftoviEncorafenibNot proven: 2 of 2 patient groups
- 2019-03-22TafinlarDabrafenibConsiderable
- 2017-10-19TafinlarDabrafenibNot proven: 3 of 3 patient groups
- 2016-03-17TafinlarDabrafenibConsiderable
- 2014-04-03TafinlarDabrafenibNot proven
- 2014-03-06ZelborafVemurafenibConsiderable
Data status: 2026-10-29